Direct comparison of in vitro susceptibility of wildtype clinical Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) to TOBI® and BRAMITOB® (Tobramycin inhalation solutions)

Journal of Cystic Fibrosis

Volumn 9, Issue 3, 2010, Pages 237-238

  Moore, John E ^a,b   Maeda, Yasunori ^a,b   Goldsmith, Colin E ^a   Rendall, Jacqueline C ^a   Elborn, J Stuart ^a,c  

^a BELFAST CITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF ULSTER   (United Kingdom)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRAMITOB; TOBRAMYCIN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC SENSITIVITY; BACTERIUM ISOLATION; BROTH DILUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; HUMAN; LETTER; LUNG INFECTION; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; PSEUDOMONAS AERUGINOSA; COMPARATIVE STUDY; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PROCEDURES; PSEUDOMONAS INFECTIONS; YOUNG ADULT;

ADMINISTRATION, INHALATION; ADULT; ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TOBRAMYCIN; YOUNG ADULT;

EID: 77953358207     PISSN: 15691993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcf.2010.03.005     Document Type: Letter

References (5)

1. Döring G, Conway SP, Heijerman HG, Hodson ME, Høiby N, Smyth A, et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000, 16:749-767.
2. Cantón R, Cobos N, de Gracia J, Baquero F, Honorato J, Gartner S, et al. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Clin Microbiol Infect 2005, 11:690-703.
3. Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ, Willey-Courand DB, et al. Cystic Fibrosis Foundation, Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007, 176:957-969.
4. Chuchalin A., Amelina E., Bianco F. Tobramycin for inhalation in cystic fibrosis: beyond respiratory improvements. Pulm Pharmacol Ther 2009, 22:526-532.
5. Poli G, Acerbi D, Pennini R, Soliani Raschini A, Corrado ME, Eichler HG, et al. Clinical pharmacology study of Bramitob, a tobramycin solution for nebulization, in comparison with Tobi. Paediatr Drugs 2007, 9(Suppl 1):3-9.